Respiratory infections

A major public health issue

Respiratory pathogens

Acute respiratory tract infections represent the main cause of acute diseases worldwide and remain the number one cause of deaths in newborns and young children

Respiratory pathogens represent a major public health issue and have a large socio-economic impact. Infections caused by several viruses, including influenza and respiratory syncytial viruses, are associated with million of days of absenteeism from work/school and, globally, represent a leading cause of consultations, hospitalizations and deaths in both developed and developing countries

Each year, worldwide, the seasonal Influenza causes 250,000 to 500,000 deaths. As example, In the United States, influenza infections alone caused up to 710,000 hospitalizations. The estimated total economic burden of flu is $88 billion, which represents around $250/American/year

Up to now, very few efficient vaccines or antiviral treatments have been reported in the medical literature to fight against these respiratory pathogens, with the exception of those available against influenza viruses. However, resistance of influenza viral strains to current antiviral agents, such as Oseltamivir (Tamiflu®) constitutes a growing medical problem. There is a real need for new antiviral strategies.

New efficient antiviral strategies are necessary

A growing market

Therapeutics for respiratory infections constitute a growing market. In an effort to treat these various acute respiratory infection, consumers spend more than $2-3 billion each year.

For example, the therapeutics market for Influenza is estimated to grow from nearly $1 billion in 2014 to nearly $1.3 billion in 2018, with an expected annual growth rate of 8% for the period of 2014-2018. Globallyl, the expected annual growth rate for the influenza market is of 3,6% for the period of 2016-2021.

The therapeutics market for Respiratory Syncytial Virus (RVS; bronchiolitis) was nearly $0.65 billion in 2014 and is estimated around $2.3 billion in 2024, with an estimated annual growth rate of 29.9% for the period of 2014-2024. Globallyl, the expected annual growth rate for the RSV market is of 14% for the period of 2014-2024.

There is currently no therapeutic strategies available in the market to treat other respiratory pathogens, such as human metapneumovirus or human coronaviruses.

Contact us

Do not hesitate to contact us!

Location
L’Atrium – 43 boulevard du 11 novembre 1918 69100 Villeurbanne, France
Phone
(+33) 478771037
Email
contact@signiatherapeutics.com
Leave a comment

Signia therapeutics.com - Copyright 2018. All right reserved.